Company Overview
About OpenBiome
OpenBiome is a Cambridge, Massachusetts-based nonprofit health research organization — backed by Y Combinator (W20) — that operated as the largest distributor of fecal microbiota transplant (FMT) products in the United States for over a decade, providing investigational FMT therapy to thousands of patients with recurrent Clostridioides difficile (C. diff) infection while accelerating research on human microbiome therapeutics. Founded in 2012, OpenBiome suspended FMT distribution as of December 31, 2024, following FDA regulatory changes that ended enforcement discretion for investigational FMT, and submitted an IND Phase 2 protocol application in November 2024 to pursue the FDA-approved clinical pathway for continued microbiome therapeutic development.
Business Model & Competitive Advantage
OpenBiome's FMT distribution model addressed the critical gap between proven clinical efficacy and patient access for one of medicine's most evidence-backed interventions: C. diff infection affects 500,000 Americans annually with 30,000+ deaths, and recurrent C. diff (failing 2+ antibiotic courses) responds to FMT at 80-90% cure rates versus 30-40% for additional antibiotics — but FMT requires a screened, tested donor stool sample that most hospital systems cannot safely source independently. OpenBiome's centralized manufacturing model (rigorous donor screening for pathogens, standardized processing for safety and efficacy, distribution to 1,000+ hospitals and outpatient centers) enabled physicians nationwide to offer FMT under FDA enforcement discretion while building the clinical evidence base that informed the FDA's eventual approval pathway. The decade of distribution data and outcomes collection made OpenBiome the world's largest clinical FMT dataset.
Competitive Landscape 2025–2026
In 2025, OpenBiome navigates the post-enforcement-discretion regulatory transition alongside commercial microbiome therapeutic companies Seres Therapeutics (NASDAQ: MCRB, VOWST approved for C. diff, FDA-approved FMT-derived therapy) and Ferring Pharmaceuticals (REBYOTA, FDA-approved live biotherapeutic for C. diff). The FDA's transition from enforcement discretion to formal drug approval pathways for FMT-derived products (driven by safety concerns about serious adverse events in immunocompromised patients) has reorganized the FMT landscape around IND-approved clinical trials and commercial biologics. OpenBiome's IND Phase 2 submission positions the nonprofit to continue contributing to microbiome research within the formal regulatory framework. The 2025 strategy focuses on completing the Phase 2 clinical trial for the IND-approved FMT program, building the research partnerships with academic medical centers for microbiome science advancement, and advocating for patient access pathways during the transition from investigational FMT to commercially approved microbiome therapeutics.
Recent Activity
View all →Material Event filed 2026-08-19
Material Event filed 2026-08-13
Quarterly Report filed 2026-08-04
Material Event filed 2026-08-04
OpenDialog July 2026 – Issue Three This month’s Q&A features the CEO and Co-Founder of the Peggy Lillis Foundation (PLF), the leading nonprofit organization that is building a nationwide C. diff (Clostridioides difficile) awareness movement by educating the public, empowering advocates, and shaping policy. He is Christian John Lillis, a tireless advocate, fundraiser and thought […]
Key Differentiators
Emerging Innovator
OpenBiome is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
S2
S2 is an AI-powered security platform focused on vulnerability discovery and attack surface management for enterprise security teams. The company's platform combines automated scanning, AI-powered ana
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Compare OpenBiome with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from OpenBiome? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim OpenBiome Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention OpenBiome vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →